CCNG1抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Jurkat, Hela and 231 cell, Primary antibody: P05678(CCNG1 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P05678(CCNG1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The CCNG1 antibody is a research tool targeting Cyclin G1 (CCNG1), a protein encoded by the *CCNG1* gene. Cyclin G1 belongs to the cyclin family, which regulates cell cycle progression by interacting with cyclin-dependent kinases (CDKs). Unlike classical cyclins, CCNG1 exhibits unique regulatory roles, including involvement in DNA damage response, cell cycle arrest, and apoptosis. It is transcriptionally activated by p53. a tumor suppressor protein, under stress conditions, suggesting its role in p53-mediated pathways. However, CCNG1 also displays p53-independent functions, complicating its mechanistic understanding.

CCNG1 is implicated in various cancers, with studies reporting both tumor-suppressive and oncogenic activities depending on context. Overexpression has been observed in breast, liver, and prostate cancers, while downregulation is linked to glioblastoma and lung cancer. This duality highlights its context-dependent role in tumorigenesis. The CCNG1 antibody is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect protein expression levels, cellular localization, and interactions in experimental models. Validated antibodies are critical for elucidating CCNG1's biological functions, its interplay with signaling networks (e.g., p53. mTOR), and potential therapeutic targeting. Researchers prioritize antibodies with high specificity, minimal cross-reactivity, and robust performance across sample types to ensure reliable data in studying CCNG1's contributions to cell cycle regulation and disease pathologies.